A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer

Authors

David B Page, Providence Cancer Center, Earle A. Chiles Research Institute Portland , OR , USAFollow
Krystle Collins
Brie Chun, Earle A. Chiles Research Institute, 4805 N.E. Glisan St., North Tower, Suite 2N87, Portland, OR, 97213, USA.Follow
Zhaoyu Sun, Earle A. Chiles Research Institute, Providence Portland Medical CenterFollow
Yoshinobu Koguchi, Robert W Franz Cancer Center, Earle A Chiles Research Institute, Portland, OR, USAFollow
William D Ryan, Department of Pathology, Providence St. Vincent Medical Center, Portland, OR, USA.Follow
Maritza Martel, Providence Portland Medical Center, Portland, ORFollow
Yaping Wu, Pathology, Providence Portland Medical CenterFollow
Nikki Moxon, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, ORFollow
Staci Mellinger, Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, ORFollow
Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.Follow
Ayca Gucalp
Tiffany A. Traina

Document Type

Article

Publication Date

2021

Publication Title

SITC 2021

Keywords

oregon; washington; chiles

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Earle A. Chiles Research Institute

Department

Oncology

Recommended Citation

Page, David B; Collins, Krystle; Chun, Brie; Sun, Zhaoyu; Koguchi, Yoshinobu; Ryan, William D; Martel, Maritza; Wu, Yaping; Moxon, Nikki; Mellinger, Staci; Urba, Walter; Gucalp, Ayca; and Traina, Tiffany A., "A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer" (2021). Articles, Abstracts, and Reports. 5533.
https://digitalcommons.providence.org/publications/5533